{"id":613130,"date":"2022-08-23T19:32:02","date_gmt":"2022-08-23T19:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=613130"},"modified":"2022-08-23T19:32:02","modified_gmt":"2022-08-23T19:32:02","slug":"growth-hormone-deficiency-market-to-accelerate-substantially-during-the-forecast-period-201932-asserts-delveinsight-key-companies-ascendis-pharma-pfizer-opko-health-lumos-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/growth-hormone-deficiency-market-to-accelerate-substantially-during-the-forecast-period-201932-asserts-delveinsight-key-companies-ascendis-pharma-pfizer-opko-health-lumos-pharma-and-others_613130.html","title":{"rendered":"Growth Hormone Deficiency Market to Accelerate Substantially During the Forecast Period (2019-32) – Asserts DelveInsight | Key Companies- Ascendis Pharma, Pfizer, Opko health, Lumos Pharma, and Others"},"content":{"rendered":"
\n
\"Growth<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Growth Hormone Deficiency Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, the rise in the number of prevalent cases of Growth Hormone Deficiency in the 7MM, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.<\/div>\n

DelveInsight’s “Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Growth Hormone Deficiency Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Growth Hormone Deficiency market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Growth<\/p>\n

Growth Hormone Deficiency: An Overview<\/strong><\/p>\n

Growth hormone deficiency (GHD) is a condition where the pituitary gland cannot make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic).<\/p>\n

A tumor may cause Growth Hormone Deficiency in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause GHD, which is known as acquired GHD (AGHD). However, in rare cases, GHD can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of Growth Hormone Deficiency (GHD) is not known or idiopathic.<\/em><\/p>\n

Growth Hormone Deficiency Market Key Facts<\/strong><\/p>\n